| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J A Frazier, J N Giedd, D Kaysen, K Albus, S Hamburger, J Alaghband-Rad, M C Lenane, K McKenna, A Breier, J L Rapopor. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. The American journal of psychiatry. vol 153. issue 4. 1996-04-24. PMID:8599409. |
the effect of clozapine on striatal morphology was examined in adolescents with childhood-onset schizophrenia. |
1996-04-24 |
2023-08-12 |
Not clear |
| E D Risby, C M Epstein, R D Jewart, B V Nguyen, W N Morgan, S C Risch, K V Thrivikraman, R L Lewin. Clozapine-induced EEG abnormalities and clinical response to clozapine. The Journal of neuropsychiatry and clinical neurosciences. vol 7. issue 4. 1996-02-27. PMID:8555749. |
the clinical eegs and the brief psychiatric rating scale (bprs) scores of 12 patients with schizophrenia and 4 patients with schizoaffective disorder were compared before and during treatment with clozapine. |
1996-02-27 |
2023-08-12 |
human |
| A Petronis, F Macciardi, A Athanassiades, A D Paterson, M Verga, H Y Meltzer, P Cola, J A Buchanan, H H Van Tol, J L Kenned. Association study between the dopamine D4 receptor gene and schizophrenia. American journal of medical genetics. vol 60. issue 5. 1996-02-13. PMID:8546161. |
the dopamine d4 receptor is of major interest in schizophrenia research due to its high affinity for the atypical neuroleptic clozapine and a high degree of variability in the receptor gene (drd4). |
1996-02-13 |
2023-08-12 |
Not clear |
| D Lacroix, Y Chaput, J P Rodriguez, M Filion, D Morrison, P St-Denis, J M Alber. Quantified EEG changes associated with a positive clinical response to clozapine in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 19. issue 5. 1996-02-07. PMID:8539424. |
quantified eeg changes associated with a positive clinical response to clozapine in schizophrenia. |
1996-02-07 |
2023-08-12 |
Not clear |
| W G Honer, G N Smith, J S Lapointe, G W MacEwan, L Kopala, S Altma. Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 13. issue 1. 1996-01-29. PMID:8526974. |
regional cortical anatomy and clozapine response in refractory schizophrenia. |
1996-01-29 |
2023-08-12 |
Not clear |
| J W Olney, N B Farbe. Glutamate receptor dysfunction and schizophrenia. Archives of general psychiatry. vol 52. issue 12. 1996-01-04. PMID:7492260. |
we propose that since n-methyl-d-aspartate receptor hypofunction can cause psychosis in humans and corticolimbic neurodegenerative changes in the rat brain, and since these changes are prevented by certain antipsychotic drugs, including atypical neuroleptic agents (clozapine, olanzapine, fluperlapine), a better understanding of the n-methyl-d-aspartate receptor hypofunction mechanism and ways of preventing its neurodegenerative consequences in the rat brain may lead to improved pharmacotherapy in schizophrenia. |
1996-01-04 |
2023-08-12 |
rat |
| D Jonsson, J Wålinde. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta psychiatrica Scandinavica. vol 92. issue 3. 1995-12-22. PMID:7484198. |
cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. |
1995-12-22 |
2023-08-12 |
Not clear |
| J S Vasile, S Steingar. Clozapine and the development of salivary gland swelling: a case study. The Journal of clinical psychiatry. vol 56. issue 11. 1995-12-12. PMID:7592503. |
clozapine is a novel antipsychotic that is effective in 30% to 50% of treatment-resistant schizophrenia. |
1995-12-12 |
2023-08-12 |
Not clear |
| M Kurz, M Hummer, I Kurzthaler, H Oberbauer, W W Fleischhacke. Efficacy of medium-dose clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 152. issue 11. 1995-12-06. PMID:7485642. |
efficacy of medium-dose clozapine for treatment-resistant schizophrenia. |
1995-12-06 |
2023-08-12 |
Not clear |
| H Y Meltze. Role of serotonin in the action of atypical antipsychotic drugs. Clinical neuroscience (New York, N.Y.). vol 3. issue 2. 1995-11-29. PMID:7583621. |
clozapine is the first of a new generation of antipsychotic drugs which constitutes a major advance in the treatment of schizophrenia. |
1995-11-29 |
2023-08-12 |
Not clear |
| Y Levkovitch, J Kronenberg, N Kayser, M Zvyagelski, B Gaoni, N Gadot. Clozapine for tardive dyskinesia in adolescents. Brain & development. vol 17. issue 3. 1995-11-13. PMID:7573764. |
this report describes the beneficial effect of clozapine on tardive dyskinesia in two adolescents with schizophrenia. |
1995-11-13 |
2023-08-12 |
Not clear |
| D Pickar, J K Hsia. Clozapine treatment of schizophrenia. JAMA. vol 274. issue 12. 1995-10-17. PMID:7674530. |
clozapine treatment of schizophrenia. |
1995-10-17 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
clozapine and the treatment of schizophrenia. |
1995-09-26 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
clozapine, an atypical antipsychotic medication, is the most significant pharmacological advancement in the treatment of chronic schizophrenia in years. |
1995-09-26 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
effective in treating the nearly 30 percent of people with schizophrenia who do not respond to conventional pharmacological and psychosocial therapies, clozapine offers new hope to many. |
1995-09-26 |
2023-08-12 |
Not clear |
| D Shore, S Matthews, J Cott, J A Lieberma. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophrenia bulletin. vol 21. issue 2. 1995-09-07. PMID:7543218. |
in september 1994, the national institute of mental health convened a group of scientists to discuss the clinical effects of rapid clozapine discontinuation, especially in light of the introduction of risperidone for the treatment of schizophrenia. |
1995-09-07 |
2023-08-12 |
Not clear |
| E R Lombertie, N Salome, P Villegier, F Laghrissi-Thode, F Nassi. [Arguments for early treatment of refractory schizophrenia]. L'Encephale. vol 21 Spec No 3. 1995-09-07. PMID:7628338. |
as such as quality of life and economy of health, it would be desirable to quickly think of alternatives neuroleptic's therapeutic protocols and clozapine in the treatment-resistant schizophrenias or those presenting an intolerance. |
1995-09-07 |
2023-08-12 |
Not clear |
| P Marti. [Medical economic impact of schizophrenia]. L'Encephale. vol 21 Spec No 3. 1995-09-07. PMID:7628346. |
although the acquisition cost of clozapine is high in comparison with that of standard antipsychotics, preliminary cost-effectiveness estimates in patients with treatment-resistant schizophrenia suggest that the clinical benefits of the drug (viz improved psychopathology; social functioning and quality of life) may confer medium to long term economic benefits, primarily by reducing the need for psychiatric hospital service. |
1995-09-07 |
2023-08-12 |
Not clear |
| Y Jin, S G Potkin, C Sandma. Clozapine increases EEG photic driving in clinical responders. Schizophrenia bulletin. vol 21. issue 2. 1995-09-07. PMID:7631173. |
photically driven electroencephalography was tested in 17 chronic schizophrenia patients who were treated with clozapine for 5 weeks. |
1995-09-07 |
2023-08-12 |
Not clear |
| J McEvoy, O Freudenreich, M McGee, C VanderZwaag, E Levin, J Ros. Clozapine decreases smoking in patients with chronic schizophrenia. Biological psychiatry. vol 37. issue 8. 1995-08-31. PMID:7619979. |
clozapine decreases smoking in patients with chronic schizophrenia. |
1995-08-31 |
2023-08-12 |
Not clear |